Spun out of University of Louisville, Koligo Therapeutics has already launched its first cell therapy product and aims to commercialise a treatment for covid-19.
Koligo Therapeutics, a US-based cell therapy developer aligned to University of Louisville, has been acquired by personalised drug producer Orgenesis for about $15m in stock.
The deal will consist of approximately 2.1 million common shares each priced at $7.00, and Orgenesis will also assume $1.3m of Koligo’s debt.
Launched in 2016, Koligo focuses on cell therapies for multiple diseases, using cellular samples extracted from the patient. Its cell-based treatment for pancreatitis, a condition where the pancreas becomes suddenly…
